Uc granted crispr patents in europe, appeals in us

Access through your institution Buy or subscribe The University of California (UC), the University of Vienna and Emmanuelle Charpentier have filed an appeal to overturn a decision by the US

Patent and Trademark Office's Patent Trial and Appeal Board (PTAB), which ruled that patents covering the use of CRISPR–Cas9 in a cellular setting, issued to the Broad Institute,

Harvard University and the Massachusetts Institute of Technology, did not interfere with patent applications filed by the UC group. In February the PTAB found that although UC's patent

application and the Broad's patents and patent application overlapped in scope, the claims in the interference are separately patentable. The appeal by the UC group, filed on April 12

in the US Court of Appeals for the Federal Circuit in Washington, seeks to have the PTAB reinstate the interference. The UC group's appeal will be bolstered by a recent decision by the

European Patent Office (EPO). In March, the EPO said it would grant a patent covering the broad use of CRISPR–Cas9 in both cellular and non-cellular settings to Dublin-based ERS Genomics,

the University of Vienna and UC, a finding that puts the EPO at odds with the USPTO. Charpentier is a cofounder of ERS Genomics, which holds the rights to her intellectual property covering

all CRISPR applications other than human therapeutics. “It is gratifying to see the EPO recognize with this broad patent the contributions of Dr. Charpentier and her colleagues on the

invention of this important technology,” said Eric Rhodes, CEO of ERS. “[W]e are hopeful that we can expect similar outcomes throughout the roughly 80 countries that use a first-to-file

system like Europe.” This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio

journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per

year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE UC granted CRISPR patents in Europe, appeals in US. _Nat Biotechnol_ 35, 396 (2017). https://doi.org/10.1038/nbt0517-396 Download citation * Published: 09 May

2017 * Issue Date: May 2017 * DOI: https://doi.org/10.1038/nbt0517-396 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link

Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative